총 66건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy Carcinoma, Non-small Cell Lung Cancer Biological: nivolumab|Biological: ipilimumab|Drug: cabozantinib|Biological: docetaxel|Biological: ramucirumab|Drug: lucitanib Bristol-Myers Squibb|Clovis Oncology, Inc.|Exelixis|Eli Lilly and Company Phase 1|Phase 2 2021-04-15
2 Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Cough Drug: Gefapixant|Drug: Placebo Merck Sharp & Dohme Corp. Phase 3 2020-05-10
3 A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer. Bladder Cancer|Bladder Tumor|Muscle-Invasive Bladder Cancer Biological: Nivolumab|Biological: NKTR-214|Procedure: Radical cystectomy (RC) Bristol-Myers Squibb|Nektar Therapeutics Phase 3 2020-01-23
4 Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) Diffuse Cutaneous Systemic Sclerosis Biological: IgPro10|Biological: Placebo CSL Behring Phase 2 2019-12-20
5 A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) Bladder Cancer Drug: nivolumab|Other: Placebo|Biological: Bacillus Calmette-Guérin (BCG) Bristol-Myers Squibb Phase 3 2019-12-09
6 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Prostate Cancer Biological: nivolumab|Drug: prednisone|Drug: docetaxel Bristol-Myers Squibb Phase 3 2019-12-06
7 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis Spondyloarthritis Drug: Upadacitinib|Drug: Placebo AbbVie Phase 3 2019-11-26
8 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) Solid Tumors Drug: Olaparib|Biological: Pembrolizumab Merck Sharp & Dohme Corp. Phase 2 2019-11-18
9 Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors Arthritis, Rheumatoid Biological: GSK3196165|Biological: Sarilumab|Drug: Placebo to GSK3196165/ Sarilumab|Drug: csDMARDs GlaxoSmithKline|Iqvia Pty Ltd Phase 3 2019-10-31
10 A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals Healthy Biological: Ad26.Mos4.HIV|Biological: Clade C and Mosaic gp140 HIV bivalent vaccine|Biological: Placebo Janssen Vaccines & Prevention B.V. Phase 3 2019-10-31